Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

ASH partners with other organizations to address knowledge gaps in AML care

The American Society of Hematology has partnered with several organizations on independent educational programming designed to help address knowledge gaps in the diagnosis and treatment of acute myeloid leukemia (AML).

8 Nov 2016

Scientists discover novel therapeutic target and treatment strategy for acute myeloid leukemia

University of Hawai'i Cancer Center researchers discovered a novel therapeutic target and treatment strategy for acute myeloid leukemia, a cancer of the blood and bone marrow that normally requires prompt and aggressive treatment.

2 Nov 2016

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials.

2 Nov 2016

Nano-biointeraction and nanopathology

Nanoparticles enter the organism in a number of ways. In most cases through inhalation and ingestion. When inhaled, the majority of them are expelled with the next breath. When ingested, most of them are gotten rid of through feces.

31 Oct 2016

Blocking critical molecule with therapeutic antibody could effectively reduce leukemia burden

Acute myeloid leukemia (AML) is an aggressive cancer known for drug resistance and relapse. In an effort to uncover new treatment strategies, researchers at University of California San Diego School of Medicine and Moores Cancer Center discovered that a cell surface molecule known as CD98 promotes AML.

27 Oct 2016

Novel lipid-based therapeutic shows promise for combating drug resistance in AML

Researchers at the Medical University of South Carolina Hollings Cancer Center have discovered a mechanism that confers resistance to drugs used to treat certain types of acute myeloid leukemia (AML).

24 Oct 2016

New oncogene may contribute to high incidence of prostate cancer among African American men

A team of scientists has identified MNX1 as a new oncogene - a gene than can cause cancer - that is more active in African American prostate cancer than in European American prostate cancer.

21 Oct 2016

Cleveland Clinic cancer researchers receive $2.4 million grant from NIH NHLBI

The National Institutes of Health National Heart, Lung and Blood Institute has awarded a $2.4 million grant over four years to Cleveland Clinic cancer researchers Jaroslaw Maciejewski, M.D., and Richard Padgett, Ph.D., to test the hypothesis that alterations in the pattern of splicing of target genes play a major role in the establishment or progression of myelodysplastic syndromes (MDS).

14 Oct 2016

Researchers awarded grant to develop safer cancer therapies for children

Two Case Western Reserve University School of Medicine researchers are receiving new funding from California-based St. Baldrick's Foundation for promising childhood cancer research.

5 Oct 2016

High out-of-pocket costs may delay Medicare patients' access to novel targeted treatment for cancer

Significant out-of-pocket costs that cancer patients can face before Medicare insurance drug benefits kick in may delay the patients' treatment with a novel class of targeted therapies, according to a University of North Carolina Lineberger Comprehensive Cancer Center-led study.

4 Oct 2016

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease.

29 Sep 2016

Antibody drug offers new therapeutic approach for treating AML

An antibody drug that targets a surface marker on cancer stem cells could offer a promising new therapeutic approach for treating acute myeloid leukemia (AML), a form of blood cancer that affects an estimated 50,000 people in Saudi Arabia.

24 Sep 2016

Novel immunotherapy shows promise against AML in clinical trial

A new type of immunotherapy shows promise against cases of acute myeloid leukemia (AML) that recur after treatment or that never respond to therapy in the first place.

21 Sep 2016

HMS scientists reveal how certain tumors develop taste for fat

Cancers are such notorious sugar addicts that PET scans searching for the disease light up when they detect sugar-gobbling tumor cells.

15 Sep 2016

Researchers uncover new molecular causes of brain cancer and leukemia

A joint research published today in Nature Communications has shown new molecular causes of brain cancer and leukemia.

14 Sep 2016

Adolescent females have low rates of pregnancy screening prior to cancer treatment

A new study indicates that adolescent females with acute leukemia have low rates of pregnancy screening prior to receiving chemotherapy that can cause birth defects.

13 Sep 2016

New drug holds potential for treating advanced mastocytosis

Most people have never heard of mastocytosis. It's a rare, sometimes deadly, immune disorder. Now new research may help those with advanced mastocytosis and possibly many more people, too.

6 Sep 2016

Researchers find new way for early prediction of leukemic relapse

Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified RNA-based biomarkers that distinguish between normal, aging hematopoietic stem cells and leukemia stem cells associated with secondary acute myeloid leukemia (sAML), a particularly problematic disease that typically afflicts older patients who have often already experienced a bout with cancer.

26 Aug 2016

FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

iCell Gene Therapeutics today (Aug. 11) announced that the Food and Drug Administration has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL).

12 Aug 2016

Researchers develop new test for early detection of patients' resistance to leukemia treatment

Australian researchers have made a world-first breakthrough in the early detection of patients' resistance to a common treatment for chronic myeloid leukemia.

28 Jul 2016